induced pluripotent stem cells

[Stemson Therapeutics] Stemson Therapeutics announced the closing of a $15 million Series A financing to advance development of Stemson’s proprietary therapeutic solution to cure hair loss. Stemson’s iPSC based technology is capable of producing the cell types required to initiate hair follicle growth and have been successfully tested in small animal models.

[Experimental Neurology] To study common disease mechanisms in amyotrophic lateral sclerosis (ALS) skeletal muscle, the authors performed RNA sequencing of skeletal myocytes differentiated from induced pluripotent stem cells derived from familial ALS and sporadic ALS patients.

[BlueRock Therapeutics LP] BlueRock Therapeutics LP announced that the US FDA has granted Fast Track designation for DA01 for advanced Parkinson’s disease. DA01, BlueRock’s PSC-derived dopaminergic neuron therapy, is under evaluation in a Phase I study.

[Methods] Researchers developed a method with microfabricated disks to scale up the generation of human midbrain organoids.

[Biomaterials] The authors established an expansion system of hPSC-derived lung progenitors based on their 3D culture in core-shell hydrogel microfibers, that ensures the maintenance of their bipotency for differentiation into alveolar and airway epithelial cells including alveolar type II cells.

[Cell] Scientists used human induced pluripotent stem cell-derived cerebral organoids expressing tau-V337M and isogenic corrected controls to discover early alterations because of the mutation that precede neurodegeneration.